

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.*



**SoftMedx Healthcare Limited**

京玖醫療健康有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 648)**

**COMPLETION OF LOAN CONVERSIONS  
INVOLVING THE ISSUE OF CONVERSION SHARES  
UNDER SPECIFIC MANDATE**

References are made to (i) the announcement dated 3 November 2023; (ii) the circular dated 30 November 2023; (iii) the poll results announcement dated 27 December 2023; (iv) the announcements dated 19 June 2024, 6 December 2024 and 16 June 2025 in relation to the supplemental restructuring agreements of SoftMedx Healthcare Limited (the “Company”). Unless the context otherwise requires, capitalised terms used herein shall have the same meaning as those defined in the circular.

**COMPLETION OF THE LOAN CONVERSIONS**

The Board announces that all conditions precedent to the Restructuring Agreement have been fulfilled and completion of the First and Second Loan Conversions simultaneously took place on 11 November 2025.

Immediately before completion of the Loan Conversions, the Company had 326,036,828 Shares in issue. 1,800,000,000 Conversion Shares have been allotted and issued as a result of the Loan Conversions. Accordingly, the Company has 2,126,036,828 Shares in issue as at the date of this announcement.

For purpose of placing down and ensuring the Company’s full compliance with the public float requirement under the Listing Rules, the Company has procured an independent placee (“Independent Placee”) and an agreement has been entered into among the Company, the Investor and the Independent Placee such that 1,593,000,000 Conversion Shares and 207,000,000 Conversion Shares were allotted and issued simultaneously to the Investor and the Independent Placee respectively. To the best knowledge, information and belief of the Directors, the Independent Placee is a third party (i) independent of the Company and its connected persons (as defined under the Listing Rules); and (ii) independent of the Investor and its connected person and not acting in concert with any of the Investor or Mr. Huang.

## EFFECT OF THE SHAREHOLDING STRUCTURE

Set out below are the shareholding structures of the Company (i) immediately prior to completion of the Loan Conversions; and (ii) immediately after completion of the Loan Conversions:

	Immediately prior to completion of Loan Conversions		Immediately after completion of Loan Conversions	
	<i>Number of Shares</i>	<i>%</i>	<i>Number of Shares</i>	<i>%</i>
The Investor	-	-	1,593,000,000	74.93%
Mr. Huang and parties acting in concert with any of the Investor and Mr. Huang	-	-	-	-
<b>Public Shareholders</b>				
Independent Placee	-	-	207,000,000	9.74%
Other public Shareholders	326,036,828	100%	326,036,828	15.33%
Subtotal	<u>326,036,828</u>	<u>100%</u>	<u>533,036,828</u>	<u>25.07%</u>
Total	<u>326,036,828</u>	<u>100%</u>	<u>2,126,036,828</u>	<u>100%</u>

For and on behalf of the board of  
**SoftMedx Healthcare Limited**  
Lam Sung Him Gaston  
Company Secretary

Hong Kong, 11 November 2025

*As at the date of this announcement, the Board comprises Mr. Lin Pinzhuo as executive Director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive Directors. All the Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement (other than those relating to the Investor) and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement (other than those expressed by the sole director of the Investor) have been arrived at after due and careful consideration and there is no other fact not contained in this announcement, the omission of which would make any statement in this announcement misleading.*

*The sole director of the Investor, Mr. Huang, accepts full responsibility for the accuracy of the information contained in this announcement (other than those relating to the Group) and confirms, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this announcement (other than those expressed by the Directors) have been arrived at after due and careful consideration and there is no other fact not contained in this announcement, the omission of which would make any statement in this announcement misleading.*